Biomarin prepares for European approval of Ascendis competitor

US firm Biomarin has upgraded its financial expectations based on Q2, and is preparing a new drug that will challenge the existing market.

The EMA HQ in Amsterdam. | Photo: Rob Acket/EMA

US biotech firm Biomarin ended the second quarter with a revenue growth of 17 percent compared to the same period last year. The result was USD 501.7m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs